33 results about "Bone marrow fibrosis" patented technology

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

The present disclosure provides methods, pharmaceutical compositions, and kits for treating cancer in patients in need thereof. The methods comprise administering to a patient in need a BET (bromodomain and extra-terminal protein) inhibitor, or a pharmaceutically acceptable salt thereof, alone or in combination with one or more JAK inhibitors. Also provided are medicaments for use in treating cancer.

The invention discloses a myelofibrosis grading prediction method and system of a full-slice image and a storage medium. The method comprises the steps of obtaining the full-slice image and a corresponding pathological detection report; inputting the full-slice image and the pathological detection report into a grading prediction model; through the hierarchical prediction model, according to the full-slice image, obtaining a full-slice image feature and a first block image feature; through the hierarchical prediction model, obtaining a first report feature and a first word segmentation feature according to the pathological detection report; reconstructing the first word segmentation feature according to the first block image feature to obtain a second word segmentation feature; obtaining a second report feature according to the second word segmentation feature; fusing the full-slice image features with the second report features to obtain fused features; and performing myelofibrosis grading prediction on the full-slice image according to the fusion features. By combining the full-slice image and the pathological detection report, the accuracy of grading prediction of myelofibrosis is improved.

Therapeutic methods and pharmaceutical compositions for treating a myeloproliferative neoplasm (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis, are described. In certain embodiments, the invention includes therapeutic methods of treating a MPN using a combination of a compound of Formula (I) or Formula (II) with a therapeutic agent selected from the group consisting of a JAK inhibitor, an IDH inhibitor, a PD-1 inhibitor, a PD-L1 inhibitor, a PD-L2 inhibitor, an interferon, a PI3K inhibitor, an AKT inhibitor, an mTOR inhibitor, a nucleoside analog, and combinations thereof.

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

The application includes a description of anti-hemojuvelin antibodies and methods for their use in the treatment of myelofibrosis and / or myelofibrosis-related conditions.

The invention provides application of combination of an mTOR inhibitor and an EPAS1 inhibitor in preparation of a medicine for treating myeloproliferative tumors, through combined use of the mTOR inhibitor everolimus and the EPAS1 inhibitor PT2385, JAK2V617F mutation-driven metabolic disorder is targeted, metabolic reprogramming is effectively reversed (the lactic acid level is reduced, the alpha-ketoglutaric acid level is increased, and the lactic acid / alpha-KG ratio is corrected), and the treatment effect on myeloproliferative tumors is improved. The JAK inhibitor can be used for treating MPN, synergistically relieving splenomegaly, reversing myelofibrosis and reducing mutation allele load, the curative effect is remarkably superior to that of existing JAK inhibitor single-drug treatment, and an innovative scheme with disease modification potential is provided for MPN.

The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions containing said polypeptides and methods of using the polypeptides to treat diseases and conditions including neuromuscular diseases, osteogenesis imperfecta, myelofibrosis, thrombocytopenia, neutropenia, and metabolic disease.

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

To provide STAT degraders and uses thereof.SOLUTION: The present invention provides compounds, compositions thereof, and methods of using the compositions. In some embodiments, the present invention provides a method of treating a hematologic malignancy selected from LGL leukemia (T cell and NK cell), cutaneous T cell lymphoma (CTCL), peripheral T cell lymphomas (PTCL, all subtypes including ALCL), diffuse large B cell lymphoma (DLBCL), acute myelogenous leukemia, multiple myeloma, and myelofibrosis.SELECTED DRAWING: None

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

The present invention belongs to the field of medicinal chemistry, relates to use of a pyrrolopyrimidine compound in the treatment of medium-risk or high-risk myelofibrosis, and specifically relates to use of a compound of formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising same in the treatment of medium-risk or high-risk myelofibrosis. The compound of formula I, the stereoisomer thereof, the pharmaceutically acceptable salt thereof, or the pharmaceutical composition thereof has a good therapeutic effect.

Heterocyclic compounds, their stereoisomers and their pharmaceutically acceptable salts are useful in the treatment of many types of cancers, such as cancers of the breast, prostate, pancreatic, gastric, lung, colon, rectum, esophagus cancer, duodenum, tongue, pharynx, liver, kidney, bile duct, uterine body, cervix, ovaries, urinary bladder, and skin. Other cancers to be treated include brain tumor, neurinoma, clear cell carcinoma, non-small cell lung cancer, small cell lung cancer, hemangioma, malignant lymphoma, malignant melanoma, thyroid cancer, bone tumor, vascular fibroma, glioblastoma, Neuroblastoma, sarcoma, neuroendocrine tumors, retinoblastoma, penile cancer, pediatric solid cancer, renal cell carcinoma, lymphoma, myeloma, leukemia, acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), chronic neutrophilic leukemia (CNL), chronic eosinophilic leukemia (CEL), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), hairy cell leukemia, cutaneous T-cell lymphoma (CTCL), multiple myeloma (MM), myeloproliferative neoplasms (MPN), Myelodysplastic syndrome (MDS), polycythemia vera (PV), essential thrombocythemia, essential thrombocytosis (ET), and myelofibrosis (MF), and also including their metastases.

Aspects of the application provide anti-hemojuvelin antibodies and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

For example, to provide a method for identifying or selecting patients who are most likely to benefit from treatment with telomerase inhibitors such as imetelstat. [Solution] This disclosure provides a method for identifying or selecting patients who are most likely to benefit from treatment with telomerase inhibitors, such as imetelstat, by testing for high molecular weight risk (HMR) based on the absence of mutations in each of JAK2, CALR, and MPL, and / or the presence of a mutation in at least one of the following genes: ASXL1, EZH2, SRSF2, and IDH1 / 2. These patients may have myelofibrosis. This disclosure also provides a method for treating myelofibrosis, the method of which includes identifying such patients.

Provided herein are compositions and methods for treating myelofibrosis in a subject. The methods comprise administering to the subject an effective amount of a compound, which is N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide or a pharmaceutical salt thereof or hydrate thereof.

This invention provides a method for treating anemia in subjects with myelofibrosis. [Solution] A method is provided for treating anemia in a subject with myelofibrosis, comprising administering an effective amount of a hemoduvelin-induced BMP signaling antagonist, a hepcidin antagonist, to the subject.

The invention features polypeptides that include an extracellular ActRIIB variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIB variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions containing said polypeptides and methods of using the polypeptides to treat diseases and conditions including neuromuscular diseases, osteogenesis imperfecta, myelofibrosis, thrombocytopenia, neutropenia, and metabolic disease.

This invention relates to use of interferon-polymer conjugates described in the specification to treat idiopathic myelofibrosis, polycythaemia vera and essential thrombocythaemia.

The present invention relates to double stranded oligonucleotides that are complementary to JAK1, leading to modulation of the expression of JAK1. Modulation of JAK1 expression is beneficial for a range of medical disorders including dry eye disease, inflammatory bowel disease, organ transplant rejection, graft-versus-host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), cancer, myelofibrosis, and asthma. Also included are compositions comprising the double stranded oligonucleotide and methods of treatment using the double stranded oligonucleotide.

The present invention relates to double stranded oligonucleotides that are complementary to JAK1, which elicit modulation of the expression of JAK1. Modulation of JAK1 expression is advantageous for a range of medical conditions including inflammatory bowel disease, organ transplant rejection, graft versus host disease, multiple sclerosis, rheumatoid arthritis (RA), juvenile idiopathic arthritis, psoriasis, dermatitis, diabetic nephropathy, systemic lupus erythematosus (SLE), dry eye disease, cancer, myelofibrosis, and asthma. The invention also includes compositions comprising the double-stranded oligonucleotides and methods of treatment using the double-stranded oligonucleotides.

Therapeutic methods and pharmaceutical compositions for treating a myeloproliferative neoplasm (MPN), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis, are described. In certain embodiments, the invention includes therapeutic methods of treating a MPN using a combination of a compound of Formula (I) or Formula (II) with a therapeutic agent selected from the group consisting of a JAK inhibitor, an IDH inhibitor, a PD-1 inhibitor, a PD-L1 inhibitor, a PD-L2 inhibitor, an interferon, a PI3K inhibitor, an AKT inhibitor, an mTOR inhibitor, a nucleoside analog, and combinations thereof.

A method for alleviating myelofibrosis includes administering to a subject in need thereof a composition including mesenchymal stem cells (MSCs). The MSCs may be selected from umbilical cord-derived mesenchymal stem cells (UCMSCs), bone marrow-derived mesenchymal stem cells (BMMSCs), adipose tissue-derived mesenchymal stem cells (AMSCs), dermis-derived mesenchymal stem cells (DMSCs), epidermis-derived mesenchymal stem cells (EMSCs), synovial membrane-derived mesenchymal stem cells (SMMSCs), dental tissue-derived mesenchymal stem cells (dental MSCs), lung-derived mesenchymal stem cells (LMSCs), and combinations thereof.

The present invention provides pharmaceutical compositions and methods of use of bisbenzylisoquinoline, e.g., 6,6',7,12-tetramethoxy-2,2'-dimethyl-berbaman, and analogs, derivatives, isomers, and modified forms of the compound, e.g., in crystalline, salt, or salt form, in combination with pharmaceutically acceptable acids or other agents, for the treatment of acute, chronic, and preleukemic conditions, as well as lymphoma and solid tumors. These include, but are not limited to, preneoplastic and neoplastic diseases and solid tumors, such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), atypical chronic myeloid leukemia (aCML), and acute myeloid leukemia (AML), polycythemia vera (PV), chronic lymphoblastic leukemia (CLL), myeloproliferative syndrome (MPS), myelodysplastic syndrome (MDS), myeloproliferative neoplasm (MPN), myelofibrosis (MF), and polycythemia vera (PV).

Aspects of the application provide hepcidin antagonists and methods of using the same in treating myelofibrosis and / or conditions associated with myelofibrosis.

Reanalysis of the SIMPLIFY 1 and 2 trials data indicates MMB is effective in JAKi-naïve patients and in second line therapy to RUX, providing benefits of reducing enlarged spleens, improving myelofibrosis-related symptoms, and increasing transfusion independence in patient at risk for thrombocytopenia from the underlying disease and RUX therapy. Accordingly, methods of treating myeloproliferative neoplasms (MPN) such as myelofibrosis are described. The methods can include administering a therapeutically effective amount of momelotinib or a pharmaceutically acceptable salt thereof to a subject identified as having (i) myelofibrosis and (ii) a platelet count of less than 150×109 / L. Also described are methods including administering to a subject with myelofibrosis a therapeutically effective stable dose of momelotinib or a pharmaceutically acceptable salt thereof, for a period of a plurality of weeks, where the subject is assessed as maintaining a platelet count above a predetermined threshold platelet count during the period.

This article provides the medical use of CXCR4-enriched regulatory T cells in combination with ruxolitinib for the treatment of myelofibrosis or to improve symptoms of myelofibrosis in subjects who have poor response to ruxolitinib monotherapy.

Regarding methods for treating myeloproliferative neoplasms. [Solution] The present invention describes therapeutic methods and pharmaceutical compositions for treating myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis. In certain embodiments, the present invention includes therapeutic methods for treating MPNs using a combination of a compound of formula (I) or formula (II) and a therapeutic agent selected from the group consisting of JAK inhibitors, IDH inhibitors, PD-1 inhibitors, PD-L1 inhibitors, PD-L2 inhibitors, interferons, PI3K inhibitors, AKT inhibitors, mTOR inhibitors, nucleoside analogs, and combinations thereof.